Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (421-430 of 666) with videos related to

Pageof 67
Sort By:
European Journal of Heart Failure|May 25, 2021
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trialPierpaolo Pellicori, David Fitchett, Mikhail N Kosiborod, et al.
Journal of the American Society of Nephrology : JASN|October 14, 2018
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME TrialChristoph Wanner, Hiddo J L Heerspink, Bernard Zinman, et al.
Plos One|August 2, 2017
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsMaarten Arends, Marieke Biegstraaten, Derralynn A Hughes, et al.
Kidney Medicine|November 2, 2023
Copeptin, Natriuretic Peptides, and Cardiovascular Outcomes in Patients With CKD: The German Chronic Kidney Disease (GCKD) StudyMarkus P Schneider, Matthias Schmid, Jennifer Nadal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 7, 2017
Mediterranean diet as the diet of choice for patients with chronic kidney diseasePhilippe Chauveau, Michel Aparicio, Vincenzo Bellizzi, et al.
Stroke|April 8, 2017
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular RiskBernard Zinman, Silvio E Inzucchi, John M Lachin, et al.
Journal of the American Society of Nephrology : JASN|July 18, 2015
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-UpMalte Lenders, Sima Canaan-Kühl, Johannes Krämer, et al.
Journal of the American Society of Nephrology : JASN|September 11, 2016
HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis PatientsChantal Kopecky, Sanam Ebtehaj, Bernd Genser, et al.
European Journal of Heart Failure|September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Felix Mahfoud, et al.
ESC Heart Failure|October 4, 2021
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trialDavid Fitchett, Silvio E Inzucchi, Bernard Zinman, et al.
Pageof 67

Showing results (421-430 of 666) with videos related to

Sort By:
Pageof 67
European Journal of Heart Failure|May 25, 2021
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trialPierpaolo Pellicori, David Fitchett, Mikhail N Kosiborod, et al.
Journal of the American Society of Nephrology : JASN|October 14, 2018
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME TrialChristoph Wanner, Hiddo J L Heerspink, Bernard Zinman, et al.
Plos One|August 2, 2017
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsMaarten Arends, Marieke Biegstraaten, Derralynn A Hughes, et al.
Kidney Medicine|November 2, 2023
Copeptin, Natriuretic Peptides, and Cardiovascular Outcomes in Patients With CKD: The German Chronic Kidney Disease (GCKD) StudyMarkus P Schneider, Matthias Schmid, Jennifer Nadal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 7, 2017
Mediterranean diet as the diet of choice for patients with chronic kidney diseasePhilippe Chauveau, Michel Aparicio, Vincenzo Bellizzi, et al.
Stroke|April 8, 2017
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular RiskBernard Zinman, Silvio E Inzucchi, John M Lachin, et al.
Journal of the American Society of Nephrology : JASN|July 18, 2015
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-UpMalte Lenders, Sima Canaan-Kühl, Johannes Krämer, et al.
Journal of the American Society of Nephrology : JASN|September 11, 2016
HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis PatientsChantal Kopecky, Sanam Ebtehaj, Bernd Genser, et al.
European Journal of Heart Failure|September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Felix Mahfoud, et al.
ESC Heart Failure|October 4, 2021
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trialDavid Fitchett, Silvio E Inzucchi, Bernard Zinman, et al.
Pageof 67